Owner : Communication Centre
Director/Editor : Rajesh agrawal
Contact : +91 7424902863
Email : thechhattisgarh@gmail.com
Reg. Address : Communication Centre, Opp. Sani
Mandir, Ram sagar para, Raipur (Chhattisgarh)

December 3, 2020

The Chhattisgarh

Beyond The Region

Country’s first indigenous corona vaccine COVAXIN to be launched on August 15

Aiming to launch the country’s first indigenous COVID-19 vaccine by 15 August, the Indian Council of Medical Research (ICMR) has called for expediting the trial of Kovaxin, a vaccine to be developed in collaboration with Bharat Biotech. The Indian Council of Medical Research (ICMR) has written a letter to Bharat Biotech asking it to run Human Trial on Fasc Track mode. ICMR has said that Bharat Biotech may release the corona vaccine test results on humans by August 15. This means that the country’s first indigenous corona vaccine Kovaxin ‘(COVAXIN) may be launched by 15 August.

ICMR has written a letter to India’s leading vaccine manufacturer Bharat Biotech, which has developed an effective vaccine ‘Kovaxin’ (COVAXIN) on the corona, to complete the human testing process of the COVID19 vaccine using the Fasc Track method. ICMR DG Balaram Bhargava has written a letter to the principal investigators of Bharat Biotech and Medical Colleges to expedite the testing process of the indigenous corona vaccine. This paper states that the process of human testing should be completed before August 15 so that clinical trial results can be launched by August 15. After this, on August 15, the first Corona vaccine made in the country ‘Kovaxin’ (COVAXIN) can be launched.

The letter states that it is the first indigenous vaccine being developed by India and is one of the highest priority projects being monitored at the highest level of government. Explain that ICMR has selected 12 institutes for trials on the country’s first indigenous Kovid-19 vaccine humans.

Bhargava has written in his letter that after completion of all clinical trials, there is a plan to launch this vaccine for the common people by 15 August. India is working steadily to meet the biotech goal, however, the end result will depend on the cooperation of all clinical trialla sites involved in the project. You have been selected as the clinical test site for the BBV152 COVID vaccine. In the wake of the COVID-19 epidemic and the urgency to launch the vaccine, you are advised to fast-track all clinical trial-related intervals in the wake of a public health emergency. All of you ensure that the trials begin on July 7.

It is worth noting that earlier a letter written by the ICMR DG to Bharat Biotech was leaked, which said that the vaccine should be ready by August 15. The letter stated that by 15 August the vaccine would require more time for public use. The letter states that please note that non-compliance will be viewed very seriously, so you are advised to make this project a top priority and complete it on the given deadline without any lapse.

12 institutes selected for trial in the country

The Indian Council of Medical Research, i.e. ICMR, has selected 12 institutes for trials on the country’s first indigenous Kovid-19 vaccine humans. One of these institutions is located in Odisha while the others are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulatur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa.

India’s first indigenous vaccine Kovaxin (COVAXIN) 

Recently, India’s leading vaccine manufacturer Bharat Biotech announced that it has made an effective vaccine Kovaxin (COVAXIN) against Corona. Not only this, ICMR has also approved Bharat Biotech Phase I and II of human trials. Bharat Biotech said in its official statement that it has prepared the vaccine in collaboration with the Indian Council of Medical Research, ie ICMR and the National Institute of Virology (NIV).

No tags for this post.